TWI732773B - 用於奈米顆粒冷凍乾燥形式的組成物及方法 - Google Patents

用於奈米顆粒冷凍乾燥形式的組成物及方法 Download PDF

Info

Publication number
TWI732773B
TWI732773B TW105123227A TW105123227A TWI732773B TW I732773 B TWI732773 B TW I732773B TW 105123227 A TW105123227 A TW 105123227A TW 105123227 A TW105123227 A TW 105123227A TW I732773 B TWI732773 B TW I732773B
Authority
TW
Taiwan
Prior art keywords
compound
cyclodextrin
composition
hydroxyalkyl
freeze
Prior art date
Application number
TW105123227A
Other languages
English (en)
Chinese (zh)
Other versions
TW201717914A (zh
Inventor
羅傑 雅達米
裕偉 王
海青 尹
立平 王
棟 劉
文彬 應
Original Assignee
日商日東電工股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日東電工股份有限公司 filed Critical 日商日東電工股份有限公司
Publication of TW201717914A publication Critical patent/TW201717914A/zh
Application granted granted Critical
Publication of TWI732773B publication Critical patent/TWI732773B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105123227A 2015-07-22 2016-07-22 用於奈米顆粒冷凍乾燥形式的組成物及方法 TWI732773B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
US62/195,356 2015-07-22

Publications (2)

Publication Number Publication Date
TW201717914A TW201717914A (zh) 2017-06-01
TWI732773B true TWI732773B (zh) 2021-07-11

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105123227A TWI732773B (zh) 2015-07-22 2016-07-22 用於奈米顆粒冷凍乾燥形式的組成物及方法

Country Status (23)

Country Link
US (3) US10300018B2 (cg-RX-API-DMAC7.html)
EP (1) EP3324932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716928B1 (cg-RX-API-DMAC7.html)
CN (2) CN113679689B (cg-RX-API-DMAC7.html)
AU (1) AU2016297153B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992849C (cg-RX-API-DMAC7.html)
CY (1) CY1123984T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324932T3 (cg-RX-API-DMAC7.html)
EA (1) EA035761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2862191T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053990T2 (cg-RX-API-DMAC7.html)
IL (2) IL288342B2 (cg-RX-API-DMAC7.html)
LT (1) LT3324932T (cg-RX-API-DMAC7.html)
MX (1) MX373982B (cg-RX-API-DMAC7.html)
PL (1) PL3324932T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324932T (cg-RX-API-DMAC7.html)
RS (1) RS61607B1 (cg-RX-API-DMAC7.html)
SI (1) SI3324932T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI732773B (cg-RX-API-DMAC7.html)
WO (1) WO2017015552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms
CA3085694A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
AU2019347774A1 (en) 2018-09-28 2021-03-25 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
JP7597334B2 (ja) * 2019-09-26 2024-12-10 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
AU2021228236A1 (en) * 2020-02-28 2022-10-06 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
WO2021216541A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL300519A (en) * 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method for lyophilization of lipid nanoparticles
WO2022071582A1 (ja) 2020-10-02 2022-04-07 国立大学法人北海道大学 脂質ナノ粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2004251680B2 (en) * 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
US20060110441A1 (en) 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 Ｃ７０含有リポソームおよびその製造方法、並びにその利用
EP2509634B1 (en) * 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2648753C2 (ru) 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3673898A1 (en) 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
KR102123129B1 (ko) 2012-03-28 2020-06-15 디스커버리 라보라토리스, 인크. 합성 리포솜 폐 계면활성제의 동결건조
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Also Published As

Publication number Publication date
IL257029A (en) 2018-03-29
US20190231695A1 (en) 2019-08-01
PT3324932T (pt) 2021-04-06
AU2016297153A1 (en) 2018-03-01
CN108024957B (zh) 2021-08-24
US20170020819A1 (en) 2017-01-26
ES2862191T3 (es) 2021-10-07
KR102716928B1 (ko) 2024-10-11
US10300018B2 (en) 2019-05-28
EA201890367A1 (ru) 2018-06-29
EP3324932B1 (en) 2021-03-10
RS61607B1 (sr) 2021-04-29
JP6875373B2 (ja) 2021-05-26
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
JP2021119161A (ja) 2021-08-12
LT3324932T (lt) 2021-04-26
IL288342B2 (en) 2024-02-01
CY1123984T1 (el) 2022-05-27
SI3324932T1 (sl) 2021-07-30
MX373982B (es) 2020-07-15
JP2018521083A (ja) 2018-08-02
IL288342A (en) 2022-01-01
EP3324932A1 (en) 2018-05-30
SMT202100196T1 (it) 2021-05-07
WO2017015552A1 (en) 2017-01-26
EA035761B1 (ru) 2020-08-06
US12311055B2 (en) 2025-05-27
US11737982B2 (en) 2023-08-29
US20240000710A1 (en) 2024-01-04
PL3324932T3 (pl) 2021-07-05
IL288342B1 (en) 2023-10-01
CA2992849C (en) 2023-06-13
AU2016297153B2 (en) 2021-02-25
DK3324932T3 (da) 2021-04-06
EP3324932A4 (en) 2019-03-06
HUE053990T2 (hu) 2021-08-30
TW201717914A (zh) 2017-06-01
CN113679689B (zh) 2023-09-01
HRP20210523T1 (hr) 2021-05-14
KR20180030698A (ko) 2018-03-23
JP7268079B2 (ja) 2023-05-02
CN108024957A (zh) 2018-05-11
CA2992849A1 (en) 2017-01-26
BR112018001178A2 (pt) 2018-09-11
CN113679689A (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
TWI355946B (en) Proliposomal and liposomal compositions of poorly
Kumar et al. Advances in self-assembled injectable hydrogels for cancer therapy
JP5923177B2 (ja) 新規な遺伝子伝達用組成物
KR101580251B1 (ko) Tpp-pcl-tpp 고분자 및 상기 고분자를 이용한 미토콘드리아 표적 나노약물전달용 조성물
CN109771663B (zh) 一种酸响应性抗癌纳米药物的制备及应用
KR20110056042A (ko) 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
Abdelaziz et al. Solid lipid nanoparticle-based drug delivery for lung cancer
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
Ghosal et al. Multi-vesicular liposome and its applications: a novel chemically modified approach for drug delivery application
Upadhyay et al. Vesicular approach review on nanocarriers bearing curcumin and applications
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
WO2005021012A1 (ja) ゲムシタビン封入薬剤担体
CN104840432A (zh) 一种紫杉烷类长循环纳米粒及其制备方法
BR112018001178B1 (pt) Composição, processo de produção de liófilo sólido, liófilo sólido, processo de preparação de um medicamento, medicamento e processo de preparação de um medicamento de ácido nucleico
Parida et al. Lipid-Based Nanocarriers: Panacea for Improving Oral Bioavailability of Lipophilic Drugs
Qiu et al. Progress in nasal drug delivery research based on biomaterials
WO2017110772A1 (ja) リポソーム及びリポソーム組成物